BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus Therapeutics on board in an intriguing $250 million upfront collaboration.
Autolus Therapeutics is expecting an FDA decision on Nov. 16 for obecabtagene autoleucel (obe-cel), its CAR-T hopeful that would rival Gilead’s Tecartus in adult acute lymphoblastic leukemia.
SAN DIEGO — Big Pharma companies aren’t the only players at #ASH23. Many biotechs — including Autolus and Gracell — who are looking to make their mark in hematology and blood cancers are also here in California to present CAR-T treatment data.
The first batch of pivotal data on Autolus Therapeutics’ CAR-T is in, and execs are ready to plot a path to market.
Autolus Therapeutics is almost ready to make a late play for the CD19 CAR-T cell therapy space. The biotech now has phase 2 data showing its asset hit the primary endpoint at an interim analysis and is setting out plans for further data to file for FDA approval next year and try to join Bristol Myers Squibb, Gilead Sciences and Novartis on the market.
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 10-13, 2022.
After kicking the tires on Autolus Therapeutics’ targeting technology, Moderna has decided to pay up for the right to use the binders in an mRNA therapy. The exercising of the option positions Moderna to use the binders in a candidate against an undisclosed immuno-oncology target.
Bristol Myers Squibb is looking for a light bulb moment, inking a deal with Autolus Therapeutics that gives the big pharma access to the biotech’s 'safety switch' for CAR-T programs.
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol Myers Squibb (NYSE: BMY). The agreement grants Bristol Myers Squibb access to incorporate Autolus’ proprietary RQR8 safety switch into an initial set of selected cell therapy programs on a target-by-target basis for the treatment of cancer, with an option for Bristol Myers Squibb to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs.
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia-...